A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Inclusion Criteria: * Patients with histologically confirmed locally advanced or metastatic solid carcinomas in Arm 1 * Patients with histologically confirmed locally advanced or metastatic colon cancer in Arm 2 * Patients with histologically confirmed locally advanced or metastatic cholangiocarcinomas in Arm 3 * Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment * Measurable disease per RECIST 1.1 (primary or metastases) Exclusion Criteria: * New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy * Pregnant or nursing women * Treatment with radiation therapy, surgery, chemotherapy, immunotherapy, or investigational therapy within four weeks prior to study entry * Unwillingness or inability to comply with procedures required in this protocol * Known active infection with HIV, hepatitis B, hepatitis C * Symptomatic brain metastases * Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor * Patients who are currently receiving any other investigational agent